schizophrenia

A Phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy

Authors: L Fredrik Jarskog, Martin T Lowy, Richard A Grove, Richard S E Keefe, Joseph P Horrigan, M Patricia Ball, Alan Breier, Robert W Buchanan, Cameron S Carter, John G Csernansky, Donald C Goff, Michael F Green, Joshua T Kantrowitz, Matcheri S Keshavan, Marc Laurelle, Jeffrey A Lieberman, Stephen R Marder, Paul Maruff, Robert P McMahon, Larry J Seidman, Margaret A Peykamian

Journal: Schizophrenia Research

Year Published: 2015

This Phase II exploratory study assessed GSK239512, a brain penetrant histamine H3 receptor antagonist, versus placebo on cognitive impairment in 50 stable outpatients with schizophrenia. Subjects were randomized to placebo or GSK239512 for 7weeks (4weeks titration). […]

CDP-choline: Effects of the procholine supplement on sensory gating and executive function in healthy volunteers stratified for low, medium and high P50 suppression

Authors: Verner Knott, Dylan Smith, Sara de la Salle, Danielle Impey, Joelle Choueiry, Elise Beaudry, Meaghan Smith, Salman Saghir, Vadim Ilivitsky, Alain Labelle

Journal: Journal of Psychopharmacology

Year Published: 2014

Diminished auditory sensory gating and associated neurocognitive deficits in schizophrenia have been linked to altered expression and function of the alpha-7 nicotinic acetycholinergic receptor (α7 nAChR), the targeting of which may have treatment potential. Choline is […]

Impaired processing speed and attention in first-episode drug naive schizophrenia with deficit syndrome

Authors: Ce Chen, Wenhui Jiang, Na Zhong, Jin Wu, Haifeng Jiang, Jiang Du, Ye Li, Xiancang Ma, Min Zhao, Kenji Hashimoto, Chengge Gao

Journal: Schizophrenia Research

Year Published: 2014

Although first-episode drug naive patients with schizophrenia are known to show cognitive impairment, the cognitive performances of these patients, who suffer deficit syndrome, compared with those who suffer non-deficit syndrome is undetermined. The aim of this […]

A comparison of the CogState Schizophrenia Battery and the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Battery in assessing cognitive impairment in chronic schizophrenia

Authors: Robert H Pietrzak, James Olver, Trevor Norman, Danijela Piskulic, Paul Maruff, Peter J Snyder

Journal: Journal of Clinical and Experimental Neuropsychology

Year Published: 2009

This study examined the criterion and construct validity of a brief computerized cognitive test battery (CogState Schizophrenia Battery) compared to a conventional cognitive test battery recommended by the Measurement and Treatment Research to Improve Cognition in […]

Criterion and construct validity of the CogState Schizophrenia Battery in Japanese patients with schizophrenia

Authors: Taisuke Yoshida, Motomu Suga, Kunimasa Arima, Yasuko Muranaka, Tsunehiko Tanaka, Satoshi Eguchi, Crystal Lin, Sumiko Yoshida, Masanori Ishikawa, Yuko Higuchi, Tomonori Seo, Yoshinori Ueoka, Masahito Tomotake, Yasuhiro Kaneda, David Darby, Paul Maruff, Masaomi Iyo, Kiyoto Kasai, Teruhiko Higuchi, Tomiki Sumiyoshi, Tetsuro Ohmori, Kiyohisa Takahashi, Kenji Hashimoto

Journal: Public Library of Science One

Year Published: 2011

Background: The CogState Schizophrenia Battery (CSB), a computerized cognitive battery, covers all the same cognitive domains as the Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) Consensus Cognitive Battery but is briefer to conduct. […]

1 3 4 5 6 7

Back to Publications